Biophytis S.A.’s (BPTS) shares surged 63.1% in the after-market hours on Apr 8, after the company announced the launch of a phase II study called OBA, with its pipeline candidate, BIO101 (20-hydroxyecdysone), to treat obesity in combination with GLP-1 receptor agonists (GLP-1 RA).Biophytis’ BIO101 is the first oral daily MAS receptor activator that is expected to prevent extensive muscle loss due to obesity treatment. Currently, approved GLP-1 RA drugs for obesity, indicated in conjunction with dieting, are ...

Biophytis (NASDAQ:BPTS) stock is rocketing higher on Tuesday after releasing its earnings results for the full year of 2023.Biophytis  is still a clinical-stage biotechnology, which means it had no revenue to report for 2023. However, its net loss for the quarter was 17.03 million euros. That’s an improvement over its net loss of 24.22 million euros in 2022.Biophytis notes there were several factors that resulted in it reporting a lower net loss. That includes reduced research and development costs due to c ...

This annual report may contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this annual report, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do n ...

• Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product Rare, genetic neuromuscular disease in male children characterized by accelerated degeneration of muscles, responsible for loss of mobility, respiratory failure and cardiomyopathy, leading to premature death. 20 21 LIVE HEALTHIER LONGER Forward Looking Statements Change from baseline at M6 Gait speed Full Analysis Set Per-Protocol Population p = 0.008 ...

UNITED STATES BIOPHYTIS S.A. Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None Table of Contents Unless otherwise indicated, "BIOPHYTIS," "the Company," "our company," "we," "us" and "our" refer to BIOPHYTIS S.A. and its consolidated subsidiaries. WASHINGTON, D.C. 20549 | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------- ...

Exhibit 99.1 Press release Biophytis regains compliance with NASDAQ minimum bid price requirement About BIOPHYTIS Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small mole ...

Exhibit 99.1 Press release The Combined General Meeting will be held on second call on April 17, 2023 Paris (France), Cambridge (Massachusetts, U.S.), March 30th, 2023, 11 Pm CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today informed that the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exhibit 99.1 Press release Biophytis' Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors Legally required documents for shareholders' votes are available on Biophytis website Paris, France, Cambridge (Massachusetts, United States), March 10, 2021, 8:00 pm CET - Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerati ...